GGHC
REGN icon

Gilder Gagnon Howe & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,707
Closed -$2.76M – 404
2020
Q4 		$2.76M Sell
5,707
-964
-14% -$520K 0.01% 238
2020
Q3 		$3.73M Sell
6,671
-314
-4% -$190K 0.02% 212
2020
Q2 		$4.36M Sell
6,985
-150
-2% -$85.1K 0.03% 183
2020
Q1 		$3.48M Buy
+7,135
New +$2.94M 0.04% 156

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's REGN Position: Q1 2021 in Review

Gilder Gagnon Howe & Co sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 5,707 shares — an estimated $2.76M sold.

Gilder Gagnon Howe & Co first reported a position in REGN in Q1 2020 and held it in 4 quarters. The position peaked at $4.36M in Q2 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • Gilder Gagnon Howe & Co reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 5,707 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $2.76M.
  • Gilder Gagnon Howe & Co first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Regeneron Pharmaceuticals position peaked at $4.36M in Q2 2020.
  • 924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2021, filed 17 May 2021.